{"title":"三环类抗抑郁药对复发性抑郁症的持续治疗。","authors":"R H Mindham","doi":"10.1159/000392256","DOIUrl":null,"url":null,"abstract":"<p><p>Patients who have suffered a depressive illness frequently relapse when treatment is stopped. A controlled study of continued medication after clinical recovery was carried out. Of 92 patients studied, 22% of those who received amitriptyline or imipramine relapsed during 6 months of observation, compared with 50% of those who received placebo. Patients who experienced persistent residual symptoms derived more benefit from the active drug during continuation treatment than those who made a complete recovery from their illness.</p>","PeriodicalId":75593,"journal":{"name":"Bibliotheca psychiatrica","volume":" 160","pages":"49-55"},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000392256","citationCount":"4","resultStr":"{\"title\":\"Continuation therapy with tricyclic antidepressants in relapsing depressive illness.\",\"authors\":\"R H Mindham\",\"doi\":\"10.1159/000392256\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Patients who have suffered a depressive illness frequently relapse when treatment is stopped. A controlled study of continued medication after clinical recovery was carried out. Of 92 patients studied, 22% of those who received amitriptyline or imipramine relapsed during 6 months of observation, compared with 50% of those who received placebo. Patients who experienced persistent residual symptoms derived more benefit from the active drug during continuation treatment than those who made a complete recovery from their illness.</p>\",\"PeriodicalId\":75593,\"journal\":{\"name\":\"Bibliotheca psychiatrica\",\"volume\":\" 160\",\"pages\":\"49-55\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000392256\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bibliotheca psychiatrica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000392256\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bibliotheca psychiatrica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000392256","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Continuation therapy with tricyclic antidepressants in relapsing depressive illness.
Patients who have suffered a depressive illness frequently relapse when treatment is stopped. A controlled study of continued medication after clinical recovery was carried out. Of 92 patients studied, 22% of those who received amitriptyline or imipramine relapsed during 6 months of observation, compared with 50% of those who received placebo. Patients who experienced persistent residual symptoms derived more benefit from the active drug during continuation treatment than those who made a complete recovery from their illness.